Style | Citing Format |
---|---|
MLA | Khalili A, Davoudabadi FAT, Sadeghi B. "Evaluation of Lipid Profiles in Patients With Chronic Spontaneous Urticaria: A Case-Control Study; [Оценка Липидного Профиля При Хронической Спонтанной Крапивнице]." Medical Immunology (Russia), vol. 27, no. 2, 2025, pp. 329-334. |
APA | Khalili A, Davoudabadi FAT, Sadeghi B (2025). Evaluation of Lipid Profiles in Patients With Chronic Spontaneous Urticaria: A Case-Control Study; [Оценка Липидного Профиля При Хронической Спонтанной Крапивнице]. Medical Immunology (Russia), 27(2), 329-334. |
Chicago | Khalili A, Davoudabadi FAT, Sadeghi B. "Evaluation of Lipid Profiles in Patients With Chronic Spontaneous Urticaria: A Case-Control Study; [Оценка Липидного Профиля При Хронической Спонтанной Крапивнице]." Medical Immunology (Russia) 27, no. 2 (2025): 329-334. |
Harvard | Khalili A, Davoudabadi FAT, Sadeghi B (2025) 'Evaluation of Lipid Profiles in Patients With Chronic Spontaneous Urticaria: A Case-Control Study; [Оценка Липидного Профиля При Хронической Спонтанной Крапивнице]', Medical Immunology (Russia), 27(2), pp. 329-334. |
Vancouver | Khalili A, Davoudabadi FAT, Sadeghi B. Evaluation of Lipid Profiles in Patients With Chronic Spontaneous Urticaria: A Case-Control Study; [Оценка Липидного Профиля При Хронической Спонтанной Крапивнице]. Medical Immunology (Russia). 2025;27(2):329-334. |
BibTex | @article{ author = {Khalili A and Davoudabadi FAT and Sadeghi B}, title = {Evaluation of Lipid Profiles in Patients With Chronic Spontaneous Urticaria: A Case-Control Study; [Оценка Липидного Профиля При Хронической Спонтанной Крапивнице]}, journal = {Medical Immunology (Russia)}, volume = {27}, number = {2}, pages = {329-334}, year = {2025} } |
RIS | TY - JOUR AU - Khalili A AU - Davoudabadi FAT AU - Sadeghi B TI - Evaluation of Lipid Profiles in Patients With Chronic Spontaneous Urticaria: A Case-Control Study; [Оценка Липидного Профиля При Хронической Спонтанной Крапивнице] JO - Medical Immunology (Russia) VL - 27 IS - 2 SP - 329 EP - 334 PY - 2025 ER - |